The FDA's Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people
Orion to receive an upfront payment of USD 290 million
MINYM can be safely used by patients above 9 years of age.
These medicines have low risk of hypoglycemia, provide beta cell protection, offer cardio-renal benefits and are safe for patients with kidney or liver conditions and senior citizens
Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
First and only PARP inhibitor to improve invasive disease-free survival in patients
It´s the first trial to demonstrate the benefits of dual pathway inhibition
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
Subscribe To Our Newsletter & Stay Updated
